Amy Barton Burns
Amy Barton Pai
PERSONAL INFORMATION
Date of Birth May 25, 1973
Place of Birth Rhinebeck, NY
Citizenship United States
FACULTY APPOINTMENTS
July 2016-present Associate Professor with Tenure
College of Pharmacy, Department of Clinical Pharmacy
University of Michigan
Ann Arbor, MI
Sept 2015-May 2016 Chair
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York
October 2014-June 2016 Professor with Tenure
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York
July 2010-June 2016 Adjunct Associate Professor of Internal Medicine
Division of Nephrology and Hypertension
Albany Medical College
Albany, New York
October 2008-October 2014 Associate Professor
Department of Pharmacy Practice
Albany College of Pharmacy and Health Sciences
Albany, New York
July 2007-September 2008 Associate Professor of Pharmacy and Nephrology with Tenure
University of New Mexico
College of Pharmacy and School of Medicine
Albuquerque, New Mexico
August 2001-June 2007 Assistant Professor of Pharmacy and Nephrology
University of New Mexico
College of Pharmacy and School of Medicine
Albuquerque, New Mexico
EDUCATION
2015-2018 Arizona State University
Master of Healthcare Innovation
1997-1999 Albany College of Pharmacy, Albany, New York Doctor of Pharmacy, magna cum laude
1993-1996 Albany College of Pharmacy, Albany, New York
Bachelor of Science in Pharmacy, cum laude
1991-1993 Dutchess Community College, Poughkeepsie, New York
Chemistry major
CERTIFICATION
December 2003 Board Certified Pharmacotherapy Specialist
Re-certified 2010
April 2012 Medication Therapy Management
LICENSURE
1996 New York- 044397
1999 Illinois- 051-287158 (inactive)
2001 New Mexico- RP00006435 (inactive)
2016 Michigan 5302045267
RESIDENCY/FELLOWSHIP EXPERIENCE
2001. Nephrology Fellowship
University of Illinois at Chicago, Chicago, IL
Mentor: Alan Lau, Pharm.D.
1996-1997 Pharmacy Practice Residency
St. Peter’s Hospital, Albany, New York
Residency Director: Thomas Lombardi, Pharm.D.
PROFESSIONAL EXPERIENCE
1997-1998 Relief Pharmacist
Price Chopper Pharmacy Albany, New York
1996-1999 Per Diem Staff Pharmacist
St. Peter’s Hospital Albany, New York
1993-1996 Pharmacy Intern/Pharmacist
Red Hook Drug Store, Red Hook, New York
1993-1995 On-Line Service Representative
Pharmacy Service Corporation of New York, Albany, New York
1989-1993 Pharmacy Technician
CVS Pharmacy, Hyde Park, New York
CLINICAL SERVICE
Oct 2016-present Nephrology Pharmacotherapy Specialist
University of Michigan Outpatient Hemodialysis
Ann Arbor, NY
Oct 2014-Jul 2016 Nephrology Pharmacotherapy Specialist
Transitions in Care Program
Dialysis Clinic Inc, Capital Region Network
Saratoga, Clifton Park, Troy, NY
June 2011-Oct 2014 Nephrology Pharmacotherapy Specialist
Rubin Dialysis/ MyMedZ MTM service
Troy, NY
Aug 2010-Jan 2013 Nephrology Pharmacotherapy Specialist
Renal Consult Service
Albany Medical Center Hospital, Albany, NY
Feb 2009-May 2011 Albany Regional Kidney Center
Hemodialysis Unit
Provide pharmaceutical care to 180 patients
Dec 2004-Oct 2008 Nephrology Pharmacotherapy Specialist
University of New Mexico Chronic Kidney Disease (CKD) clinic
Triage patients, recommend optimal therapies, screen for anemia and secondary hyperparathyroidism.
Aug 2001-Oct 2008 Nephrology Pharmacotherapy Specialist
Dialysis Clinic, Inc. outpatient hemodialysis unit, Albuquerque, NM
Provide pharmaceutical care to 175 patients, participate in weekly and monthly rounds, initiate and revise drug policy and procedures, provide inservices to staff.
PUBLICATIONS
Original Research
Jang SM, Jiang R, Grabe D, Pai AB. Assessment of Literacy and Numeracy Skills Related To Non-Steroidal Anti-Inflammatory Drug (NSAID) Labels. (submitted: Int J Pharmacy Practice)
Jang SM, Parker W, Pai AB, Jiang R, Cardone K. Assessment of Literacy and Numeracy Skills Related to Medication Labels in Chronic In-center Hemodialysis Patients. (submitted: Clinical Nephrology)
Pai AB, Garba A, Prokopienko A, Neumann P, Narsipur S,. Quantification of Lipoteichoic Acid in Dialysis Patients with Central Venous Catheters. (Submitted: Frontiers in Medicine:Nephrology)
Pai AB, Pai MP, Meyer DE, Bales BC, Cotero VE, Zheng N, Jiang, W. In Vitro and In Vivo DFO-chelatable Labile Iron Release Profiles Among Commercially Available Intravenous Iron Nanoparticle Formulations. Regul Toxicol Pharmacol. 2018 May 29 PMID:29857115
Flythe J, Hilliard T, Castillo C, Ikeler, Orazi, J, Abdel-Rahman, E, Pai AB, Rivara, M, St. Peter WL, PharmD, Weisbord, SD MD, Wilkie, C, Mehrotra, R. Symptom Prioritization among Adults Receiving In-Center Hemodialysis: A Mixed-Methods Study. Clin J Am Soc Nephrol. 2018 May 7;13(5):735-745 PMID: 29559445
Pai AB, Meyer D, Bales B, Cotero V, Pai MP, Zheng N, Jiang W. Performance of redox active and chelatable iron assays to determine labile iron release for intravenous iron formulations. Clin Transl Sci. 2017 Feb 3. PMID:28160427
Pai AB, Grabe DW, Eisele G, Patel H, Kubotera S, Prokopienko A, Nolin T. Changes in plasma levels of asymmetric dimethylarginine in chronic kidney disease patients treated for 8 weeks with the vitamin D receptor agonist paricalcitol. J Res Development. 2015;3:2
Jang S, Prokopienko AJ, Grabe DW, Cerulli J, Fox C, Vassalotti J, Pai AB. NSAID-Avoidance Education in Community Pharmacies for Patients at High Risk for Acute Kidney Injury, Upstate New York, 2011. Prev Chronic Dis. 2014 Dec 18;11:E220 PMID:25523351
Asif A, Carrillo R, Garisto JD, Monrroy M, Khan RA, Castro H, Merrill D, Ali AS, Pai AB, Waldman J, Salman L. Prevalence of Chronic Kidney Disease in Patients Undergoing Cardiac Rhythm Device Removal. Semin Dial. Semin Dial. 2013 Jan-Feb;26(1):111-3 PMID: 22780814
Pai AB, Patel H, Prokopienko A, Gertzberg N, Alsaffar H, Neumann P, Punjabi A, Johnson A. Lipoteichoic acid from Staphylococcus aureus induces lung endothelial cell barrier dysfunction: role of reactive oxygen and nitrogen species. Plos One 2012;7(11):e49209 PMID: 23166614
Conner TA, McQuade CR, Olp J, Pai AB. Effect of Intravenous Vitamin C on Reactive Oxygen Species Generation, Cytokine Activation and Oxidative Stress in Hemodialysis (HD) Patients Receiving Intravenous Iron Sucrose (IS). Biometals. 2012 Oct;25(5):961-9 PMID: 22706571
Pai AB. Feleder C, Johnson A. Tumor Necrosis Factor-α (TNF) induces increased lung vascular permeability: a role for GSK3α/b. Eur J Pharmacol. 2011 Apr 25;657(1-3):159-66 PMID: 21316358
Pai AB, McQuade C, Olp J. Hicks P, Conner T. Non-transferrin Bound Iron (NTBI), Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). Biometals. 2011 Aug;24(4):603-13 PMID: 21229380
Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai AB. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrology 2010:11;16 PMID: 20716362
Pai AB, Nielson JC, Kausz A, Miller P, Owen J. Plasma Pharmacokinetics of two consecutive doses of ferumoxytol in Healthy Subjects. Clin Pharmacol Ther 2010;June 30:1-5 PMID: 20592725
Pai AB, Depczynski JC, Martinez I, Boyd A, Khan N, Manley HJ. Reduced Drug Use Hospitalization Rates in Patients Undergoing Hemodialysis Who Received Pharmaceutical Care-a 2 year randomized, controlled study. Pharmacotherapy 2009;29(12):1433-1440 PMID: 19947803
Demirovic J, Pai AB, Pai MP. Creatinine Clearance Estimation in Morbidly Obese Patients. Am J Health Syst Pharm 2009;66(7)642-648 PMID: 19299371
Boyd A, McQuade CR, Conner TA, Manley HJ, Pai AB. Correlation between the Renal Quality of Life Profile (RQLP) and Short Form−36 (SF−36) in a United States (US) Hemodialysis (HD) Population. Letter. Hemodial Int 2009;89-90 PMID: 19210284
Pai AB, Boyd A, Chavez A, Manley HJ. Health-related Quality of Life is Maintained in Hemodialysis Patients Receiving Pharmaceutical Care-A 2-Year Randomized, Controlled Study. Hemodial Int; 2009;13:72-79 PMID: 19210281
Pai AB, Norenberg JP, Boyd A, Raj DSC, Chan L. Intravenous Iron is Associated with Increased Cytochrome P-450 3A4 (CYP3A4) Activity in Hemodialysis (HD) Patients. Clin Ther 2007;29:2699-2705 PMID: 18201586
Pai AB, Harford A, Boyd AV, McQuade C, Norenberg JP, Zager P. Comparison of oxidative stress markers in hemodialysis patients following administration of iron dextran, sodium ferric gluconate and iron sucrose. Pharmacotherapy 2007;27:343-350. PMID: 17316146
Boyd AV, Townsend K, Dunne A, Spalding CT Pai AB. Optimal sampling for international normalized ratios in hemodialysis patients with central venous catheters. Nephrol Nurs J 2006;33:408 PMID: 17001998
Pai AB, Depczynski J, Pai MP, McQuade C, Mercier RC. Non‑transferrin bound iron is associated with enhanced staphylococcus aureus growth in hemodialysis patients receiving intravenous iron sucrose. Am J Nephrol 2006;26:304‑309 PMID: 16809897
Raj DSC, Dominic EA, Pai A, Osman F, Morgan M, Pickett G, Shah VO, Ferrando A, Moseley P: Skeletal muscle, cytokines and oxidative stress in End-stage renal disease. Kidney Int 2005;68:2338-2344 PMID: 16221238
Pai AB, Pai MP. A limited sampling algorithm for vancomycin dosing during hi-flux hemodialysis. Am J Health Syst Pharm 2004;61:1812-6 PMID: 15462252
Pai AB, Lin S, Arruda J, Lau AH. Long-term therapy with paricalcitol for secondary hyperparathyroidism in hemodialysis patients. Int J Artif Organs 2003;26(6):484-90 PMID: 12866654
Pai AB, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients Clinical Nephrology 2002;58:38-46 PMID: 12141405
Barton AE, Levin GM. Evaluating the incidence of antidepressant-induced sexual dysfunction Hospital Pharmacy 2000 Jun:35(6);609-613
Case Reports
McQuade CM, Griego J, Anderson J, Pai AB. Dose-dependent elevation in serum creatinine associated with fenofibrate therapy. Am J Health Syst Pharm. 2008;65:138-41 PMID: 18192258
Carson J, Gold L, Barton A, Biss R. Fatality and interferon alpha for malignant melanoma. Lancet (letter) 1998 Oct 31; 352(9138): 1443-4 PMID: 9807998
Barton A Burns, Bailie GR, Eisele G, McGoldrick D, Rosano TG, Swift T. Use of pharmacokinetics to determine the duration of dialysis in management of methanol poisoning Am J Emerg Med. 1998 Sep;16(5):538-40 PMID: 9725978
Review Articles and Editorials
Pai AB, Divine H, Marciniak M, Morreale A, Saseen J, Say K, Segal A, Norton, J, Narva A. for the National Kidney Disease Education Program Pharmacy Working Group. Judicious Use of Non-steroidal Anti-inflammatory Drugs to Avoid Community-Acquired Acute Kidney Injury. (Accepted: Annals of Pharmacotherapy)
Pai AB. Why Nomenclature for Pharmacist-Led Interventions Matters: Conquering the State of Confusion. Clin J Am Soc Nephrol. 2018 Jan 2. Invited editorial PMID:29295828
Pai AB. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation. Ann N Y Acad Sci. 2017 Nov;1407(1):17-25 PMID: 29027212
Galura G., Pai AB., Health Literacy and Medication Management in Chronic Kidney Disease. HLRP: Health Literacy Research and Practice. 2017;1(3) e109-e115. doi: 10.3928/24748307-20170607-01
Astier A, Pai AB, Bissig M, Crommelin DJA, Flühmann B, Hecq JD, Knoeff, J, Lipp H, Morell-Baladrón A, Mühlebach S. How to select a nanosimilar. 2017 Ann N Y Acad Sci. doi: 10.1111/nyas.13382 PMID:28715605
Pai AB, It’s all about ADME. Adv in Chronic Kidney Dis. 2016 Mar;23(2):76-81
Schwenk M., Pai AB. Drug Transporter Function-Implications in Chronic Kidney Disease. Adv in Chronic Kidney Dis. 2016 Mar;23(2):61-2
Gilmartin C, Pai AB, Hughes D, Hilal N. Risky business: Lessons from medication misadventures in chronic kidney disease. Physician Assist Clinic 2016;1:55-76
Pai AB, Jang S, Wegryzn N. Iron-based Phosphate Binders-A New Element for Treatment of Hyperphosphatemia in Kidney Disease. Expert Opin. Metab. Toxicol.. 2016 Jan;12(1):115-27
Pai AB. Keeping Kidneys Safe: The Pharmacist’s Role in NSAID Avoidance in High-Risk Patients. J Am Pharm Assoc (2003). 2015 Jan 1;55(1):e15-25 PMID:25503987
Pai AB. Evaluating Plasma Pharmacokinetics of IV Iron Formulations: Judging Books by Their Covers? Clin Pharmacokinet 2015:54(4);323-4
Charytan DM, Pai AB, Chan CT, Coyne DW, Hung AM, Kovesdy CP, Fishbane S, On behalf of the American Society of Nephrology Dialysis Advisory Group. Considerations and Challenges in Defining the Optimal Utilization of Iron in Dialysis-Dependent Chronic Kidney Disease. Invited Commentary, J Am Soc Nephrol. 2015;26(6):1238-1247 PMID:25542967
Manley HJ, Pai AB. Integrated Pharmacy Services: a necessary component for ESRD patient care. Am J Kidney Dis 2013; Sep;62(3):445-7 PMID: 23972057
Pai AB, Cardone KE, Manley HJ, St. Peter W, Shaffer R, Somers M, Mehrotra R. Medication Reconciliation and Therapy Management in Dialysis-Dependent Patients: Need for a Systematic Approach. Clin J Am Soc Nephrol. Invited Commentary. 2013 Nov;8(11):1988-99 PMID: 23990162
Pai AB, Garba AO. Ferumoxytol: a silver lining in the treatment of anemia of chronic kidney disease: or another dark cloud? Journal of Blood Medicine 2012;3:77-85 PMID: 22973119
Kubotera N, Prokopienko A, Garba AO, Pai AB. Endotoxin Binding by Sevelamer: Potential Impact on Nutritional Status. Int J Nephrol. 2013;2013:954956. PMID: 23401772
Moore CL, Pai AB. CKD: Pharmacotherapy in a House of Mirrors. (editorial) Adv in Chronic Kidney Dis. 2010;17:381-83 PMID: 20727507
Cardone KE, Bacchus S, Assimon M, Pai AB, Manley HJ. Medication-Related Problems in Chronic Kidney Disease. Adv in Chronic Kidney Dis 2010;17:404-412 PMID: 20727510
Assimon M, Mousa S, Shaker O, Pai AB. The Effect of Sevelamer Hydrochloride and Calcium Based Phosphate Binders on Mortality in Hemodialysis Patients: A Need for More Research. Consultant Pharm. 2010;35:37-51 PMID: 20211816
Pai AB, Conner TA, McQuade CR. Therapeutic Use of the phosphate binder Lanthanum Carbonate. Expert Opin Drug Metab and Toxicol 2009; 5 (1):71-81 PMID: 19236230
Pai AB, Conner TA. Oxidative Stress and Inflammation in Chronic Kidney Disease: Role of Intravenous Iron and Vitamin D. J Pharm Prac 2008;21:214-224
Pai AB. Broader Roles of Vitamin D in Patients with Chronic Kidney Disease. Kidney: A Current Survey of World Literature. 2006;15:199-201
Pai AB, Pai MP. Optimizing Antimicrobial Therapy for Gram-positive Bloodstream Infections in Patients on Hemodialysis. Adv in CKD 2006; Jul;13(3):259-70 PMID: 16815231
Martinez I, Pai AB. Use of antibiotic lock solutions in hemodialysis catheter-related bloodstream infections. Kidney: A Current Survey of World Literature. 2005;14:53-56
Pai AB, Smeeding JE, Brook RA. The role of sevelamer in achieving the kidney disease outcome quality initiative (K/DOQI) for hyperphosphatemia. Curr Med Res Opin. 2004;20:991-999 PMID: 15265243
Pai AB. Intravenous iron and bacteremia in hemodialysis patients. Kidney: A Current Survey of World Literature. 2004;13:51-53
Pai AB. Warfarin for prevention of vascular access thrombosis in hemodialysis patients. Kidney: A Current Survey of World Literature. 2003;12:201-203
Pai AB. Iron and oxidative stress. Kidney: A Current Survey of World Literature. 2003;12:53-56
Smith HS, Barton AE. Tizanidine in management of spasticity and musculoskeletal complaints in the palliative care population. American Journal of Hospice and Palliative Care 2000 Jan/Feb:17(1);50-58 PMID: 11094920
ABSTRACTS
Costello G, Dean, M, Codd C, Yin Y, Galura G, Pai AB. A mobile application to evaluate patient preference for NSAID avoidance education media. Am J Kid Dis. 2018;71(4):510
Pai AB, Meyer D, Bales B, Cotero V, Pai MP. Bioequivalence Evaluation of Generic Intravenous Iron Products-Implications of labile iron release. International Bioiron Society. May 8, 2017. Los Angeles, CA
Pai AB, Neumann, PH, Regis, T. Differential oxidative stress and endothelial dysfunction responses Induced By brand and generic sodium ferric gluconate complex formulations. International Bioiron Society. May 8, 2017. Los Angeles, CA
Pai AB, Polanco N, Garfinkel M, Mansour V. Assessing literacy skills related to NSAID medication labeling in primary care. American Society of Nephrology Kidney Week; November 19, 2016, Chicago, IL
Pai AB, Meyer D, Bales B, Cotero V, Pai MP. Labile iron release from intravenous iron formulation: considerations for bioequivalence. Global Summit on Regulatory Science: Nanotechnology Standards and Applications. National Institutes of Health, Bethesda, MD, September 12, 2016
Wegrzyn NM, Parker WM, Pai AB, Daoui R, Daoui S, Cardone KE. Assessing health literacy in outpatient nephrology patients. Abstract accepted: National Kidney Foundation Spring Clinical Meeting; April 28, 2016, Boston, MA.
Raouf M, Kelsey T, Wilming C, Cabral K, LaFleur C, Pai AB. A student pharmacist-led public health initiative for early identification of cardiovascular and kidney disease risk factors. American College of Clinical Pharmacy Global Conference, October 19, 2015, San Francisco, CA.
Pai AB, Meyer D, Bales B, Cotero V, Pai A, Zheng N, Jiang W. Labile Iron Release From Intravenous (IV) Iron Formulations: Considerations For Bioequivalence. National Kidney Foundation Spring Clinical Meeting. March 27, 2015
Pai AB, Cardone K, Daoui R, Salenger P, Chen X, Kao T, Boverman G, Davenport D.
Utility Of Bioelectrical Impedance Spectroscopy (BIS) With Electrical Impedance Tomography (Eit) To Evaluate Regional Volume Flux In Hemodialysis (HD) Patients. National Kidney Foundation Spring Clinical Meeting. March 27, 2015
Pai AB, Narsipur S, Goldstein L. Lipoteichoic Acid As A Non-Invasive Marker Of Biofilm Burden In Hemodialysis (HD) Patients. National Kidney Foundation Spring Clinical Meeting. March 27, 2015
Pai AB, Meyer D, Bales B, Cotero V, Pai M, Zheng N, Jiang W. Performance of redox active and chelatable iron assays to determine labile iron concentrations from intravenous iron formulations. Innovation@CDER, Center for Drug Evaluation and Research, September 10, 2014, Silver Spring, MD
Assessing Literacy and Numeracy Skills Relating to Medication Labeling in Patients on Dialysis. Cho S, Parker W, Teoh B, Pai AB, Cardone KE. National Kidney Foundation Spring Clinical Meeting. Las Vegas, NV April 23, 2014
Pai AB, Garba AO, Waldman J. A Non-Invasive Approach to Evaluation of Biofilm Burden in Hemodialysis Patients. American Society of Nephrology Renal Week. November 6, 2013. Atlanta, GA
Peres de Alcantara D, Prokopienko AJ, Cardone K, Pai AB. Medication Management Services for Dialysis Patients in Brazil-A Survey of Clinicians. American College of Clinical Pharmacy, October 14, 2013, Albuquerque, NM.
Prokopienko A, Lawuyi A, Gertzberg N, Neumann P, Johnson A, Pai AB. Differential Effect of IV Iron Compounds on Intracellular Labile Iron Pool in Aortic Coronary Endothelial Cells. American College of Clinical Pharmacology. Bethesda, MD. September 20, 2013.
Cardone KE, Parker W, Pai AB, Cavanaugh K. Assessment of medication label literacy and numeracy skills in hemodialysis patients. National Kidney Foundation 2013 Spring Clinical Meeting, April 2-6, 2013; Orlando, FL. Poster #117; Poster presentation.
Patel H. Kubotera N, Prokopienko A. Cardone KE, Pai AB. Usage of Erythropoiesis Stimulating Agents Pre and Post Bundle. American Society of Health-systems Pharmacists Mid-Year Clinical Meeting, December 7, 2011, New Orleans, LA
Patel HV, Prokopienko AJ, Gertzberg N, Neumann P, Johnson A, Pai AB. Differential Effect of IV Iron Compounds on Intracellular Reactive Oxygen Species (ROS) Generation in Aortic Coronary Endothelial Cells. American College of Clinical Pharmacy Annual Meeting (Best Student Paper Finalist). October 17, 2011, Pittsburgh, PA
Cardone KE, Fox B, Meola S, Goldstein L, Hoy C, Salenger P, Pai AB. Effects of the ESRD Medicare Bundling Rule on Anemia Management in Private Dialysis Units. American Society of Nephrology Renal Week. November 11, 2011, Philadelphia, PA
Pai AB, Grabe DW, Eisele G. Effect of the Vitamin D receptor Agonist Paricalcitol on Cell Adhesion Markers and ADMA in CKD 3 and 4. ERA-EDTA Annual Meeting, June 24, 2011, Prague, Czech Republic
Sidile J, Der Mesorpian P, Makary Y, Pai AB, Haqqie S. Evaluation of Predictive Factors of Potassium Derangement in Therapeutic Hypothermia. National Kidney Foundation, Spring Clinical Meeting. April 27, 2011, Las Vegas, NV
Pai AB, Johnson A, Role of Intravenous Iron Compounds in Pathogenesis of Pulmonary Edema. ASN Renal Week, November 17-21, 2010, Denver, CO
Pai AB, Johnson A. Lipoteichoic Acid (LTA) Induced Lung Endothelial Barrier Dysfunction: Possible Role of Endothelial Nitric Oxide (eNOS). ASN Renal Week, November 17-21, 2010, Denver, CO
Pai AB, Grabe DW, Eisele G. Effect of the Vitamin D receptor Agonist Paricalcitol on Biomarkers of Vascular Reactivity in CKD 3 and 4. ASN Renal Week, November 17-21, 2010, Denver, CO
Johnson A, Pai A. Lipotechoic acid (LTA) causes reactive oxygen species dependent lung endothelial barrier dysfunction. American Thoracic Society, May 17, 2010, New Orleans, LA
Pai AB, Gertzberg N, Neumann P, Johnson A. Role of Lipotechoic acid from Staphylococcus aureus in Pathogenesis of Pulmonary Edema. ASN Renal Week, October 30, 2009, San Diego, CA
Conner T, Raj D, McQuade C, Olp J, Pai AB, Effect of Intravenous Ascorbic Acid on Cytokine Activation and Oxidative Stress in Hemodialysis (HD) Patients Receiving Intravenous Iron Sucrose (IS). ASN Renal Week, November 6, 2008, Philadelphia, PA
Pai AB, Raj D, McQuade C, Olp J. Hicks P, Conner T. Non-transferrin Bound Iron (NTBI), Cytokine Activation and Intracellular Reactive Oxygen Species Generation in hemodialysis (HD) Patients Receiving Iron Dextran (ID) or Iron Sucrose (IS). ASN Renal Week, November 6, 2008, Philadelphia, PA
Pai AB, Owen J, Clarkin M, Nielson J, Clark T. Lawler D, Kausz A. Plasma Pharmacokinetic (PK) Profile of Ferumoxytol in Healthy Subjects. Annual Meeting of the American Society of Nephrology, ASN Renal Week. November 4, 2007. San Francisco, CA
Boyd A, McQuade CR, Manley HJ, Pai AB. Correlation between the Renal Quality of Life Profile (RQLP) and Short Form−36 (SF−36) in a United States (US) Hemodialysis (HD) Population. Abstract SU−PO1099. Annual Meeting of the American Society of Nephrology, ASN Renal Week. November 4, 2007. San Francisco, CA
Demirovic J, Pai AB, Conner TC, Pai M. Comparison of Nafcillin and Cefazolin for Methicillin Sensitive Staphylococcus aureus (MSSA) Related Bloodstream Infections (BSI) in Hemodialysis (HD) Patients. Annual Meeting of the American Society of Nephrology, ASN Renal Week. November 4, 2007. San Francisco, CA
McQuade CR, Boyd AV, Conner T, Pai AB. Clinical pharmacy research training program (CPRTP): a longitudinal approach to career development. Abstract # 268. Annual Meeting of the American College of Clinical Pharmacy. October 16, 2007. Denver, CO
Pai AB, Norenberg JP, Boyd AV, Raj DSC, MD, Chan L, Intravenous Iron is Associated with Increased Cytochrome P-450 3A4 (CYP3A4) Activity in Hemodialysis (HD) Patients J Am Soc Nephrol 2006;17:481A
Horton E, Pai AB, Anselmo L, Garcia D. Case-control analysis of prophylactic enoxaparin therapy in obese patients. American College of Clinical Pharmacy, October 28, 2006 St. Louis, MO
McQuade C, Boyd A, Chavez A, Burke R, Pai AB. Factors associated with hypocalcemia in hemodialysis patients receiving cinacalcet HCL for secondary hyperparathyroidism. American College of Clinical Pharmacy, October 29, 2006 St. Louis, MO
Pai AB, Depczynski JC, Martinez I, Boyd A, Chavez A, Manley HJ. Impact of Clinical Pharmacy Services on Medication Costs, Hospitalization Rates and Drug-Related Problems in Hemodialysis (HD) Patients. J Am Soc Nephrol 2005;16:725A
Pai AB, Pai M, Raj DSC. Hemodialysis Clearance of Amino Acids (AA) during Intradialytic Supplementation.
J Am Soc Nephrol 2005;16:717A
Pai AB, Adeniyi O, Osman F, Shah V, Ferrando A, Raj DSC. Amino Acid and Protein Kinetics in ESRD Patients with Type-2 Diabetes Mellitus.
J Am Soc Nephrol 2005;16:714A
Osman F, Adeniyi O, Varghese E, Shah V, Waters D, Pai AB, Ferrando A, Raj DSC. Amino Acid Infusion Does Not Decrease Protein Catabolism during Hemodialysis.
J Am Soc Nephrol 2005;16:48A
Pai AB, Pai M, Depczynski JC, McQuade C, Mercier RC. Effect of Non-Transferrin Bound Iron on Staphylococcus aureus Growth in Hemodialysis Patients Receiving Intravenous Iron Sucrose.
J Am Soc Nephrol 2005;16:453A
Pai AB, Boyd A, Chavez A, Manley HJ. Assessment of quality of life in hemodialysis patients receiving pharmaceutical care. Pharmacotherapy 2005;25:1466
Pai AB, Harford A, Boyd A, McQuade C, Zager P. Comparison of Oxidative Stress Markers in Hemodialysis (HD) Patients Receiving Iron Dextran (ID), Sodium Ferric Gluconate (SFG) and Iron Sucrose (IS). Pharmacotherapy 2005;25:1513
Martinez I, Pai AB. Frequency of Hyperkalemia in Hemodialysis Patients on Angiotensin-Converting Enzyme Inhibitors (ACE-I) and Angiotensin Receptor Blocker Therapy. American College of Clinical Pharmacy, Spring Meeting, April 12, 2005, Myrtle Beach, SC.
Calhoun W, Pai A, Morgan M, Pickett G, Shah V, Raj D. Skeletal Muscle Is an Important Source of Interleukin-6 and Oxidative Stress in End-Stage Renal Disease (ESRD) J Am Soc Nephrol 2004;SAPO790
Depczynski JC, Pai AB, Boyd A, Manley HJ. A Randomized Study to Determine the Impact of Clinical Pharmacy Services on Medication Costs, Hospitalization Rates and Quality of Life in Hemodialysis Patients. American Society of Helath-Systems Pharmacists Mid-year meeting. December 11, 2003. New Orleans, LA
Harford A, Stidley C, Hunt C, Paine S, Pai AB, Scavini M. Brown R, Zager P. Iron Dose and Survival in Hemodialysis Patients. J Am Soc Nephrol 2003:14;266
Boyd A, Pai AB, Townsend K, Tinklenberg A, Spalding CT. Optimal Sampling for International Normalized Ratios in Hemodialysis Patients with Central Venous Catheters. J Am Soc Nephrol 2003:14;729A
Stidely CS, Sun Y, Harford A, Brown R, Pai AB, Zager PG. Increased mortality in hemodialysis patients receiving no iron and high dose iron therapy. Abstract # 554358 World Congress of Nephrology, Berlin, Germany. June 8-12 2003
Pai AB, Brown R, Spalding CT, Zager P. Clotting events within target INR ranges in hemodialysis patients treated with warfarin. (Abstract # F-PO826) J Am Soc Nephrol 2002:13;229A
Pai AB, Lin S, Arruda J, Lau A. Long-term therapeutic effects of paricalcitol in hemodialysis patients. (Abstract # A0304) J Am Soc Nephrol 2000:11;56A
Pai AB, Chretien C, Lau AH. The effects of nandrolone decanoate on nutritional parameters in hemodialysis patients. (Abstract # 153) American College of Clinical Pharmacy Annual Meeting Los Angeles, CA November, 2000
Pai AB, Lin S, Lau AH. Evaluating Long-term therapy with paricalcitol in hemodialysis patients. (Abstract # 190) American College of Clinical Pharmacy Spring Practice and Research Forum, Monterey, CA April 2000
Lin S, Pai AB, Lau AH. Correlation of patient variables to abnormal lipid profiles in the hemodialysis population. (Abstract # 189) American College of Clinical Pharmacy Spring Practice and Research Forum, Monterey, CA April 2000
Barton AB, Carson J, Lombardi TP. Evaluating Diuretic Resistance and Implementation of Therapeutic Substitution; Torsemide for Bumetanide. (Abstract #150) 16th Annual Conference for Pharmacy Residents and Preceptors, Baltimore, MD May 1997
OTHER PUBLICATIONS
Wilkerson T, Pai AB. Optimizing Pharmacotherapy in Chronic Kidney Disease– The Role of the Clinical Pharmacist. Pharmacist Quarterly, Phoenix Indian Medical Center. March 2007
Ault A. Preventing ESRD Drug Interactions. Internal Medicine News. January 15, 2006. (press release based on abstract presented at American Society of Nephrology Meeting, November 2005)
Pai AB. Summary of Recent Studies of Dual Blockade of the Renin-Angiotensin-Aldosterone-System with ACE-inhibitors(ACEI) and Angiotensin Receptor Blockers(ARB) in Diabetic Kidney Disease. American College of Clinical Pharmacy Nephrology PRN Newsletter. July 2005
Martinez I, Pai AB. Antibiotic Lock Solutions for Hemodialysis Catheter-related Bloodstream Infections. American College of Clinical Pharmacy Nephrology PRN Newsletter. March 2005
Koertner B, Pai AB, Impact of National Kidney Foundation Kidney Disease Outcome Quality Initiative Guidelines on Treatment of Renal Osteodystrophy in Hemodialysis Patients. American College of Clinical Pharmacy Nephrology PRN Newsletter. March 2004
Ponto JA, Pai AB (guest editor).Radiopharmaceuticals and Dialysis. Correspondence Continuing Education Courses for Nuclear Pharmacists and Nuclear Medicine Professionals. 2002;10(1):1-37
Pai AB. Lead in Calcium Supplements. American College of Clinical Pharmacy Nephrology PRN Newsletter. September 2002
Barton AB, Carson J. The clinical use of loop diuretics in congestive heart failure and chronic renal insufficiency. Therapeutic Forum-St. Peter’s Hospital, October 1996
BOOK CHAPTERS
Pai AB. Iron Oxide Nanoparticle Formulations for Supplementation. in Metal Ions in Life Sciences. 1st Edition, 2018 Springer Nature Switzerland AG,
Pai AB, Wegrzyn N. Acute Kidney Diseases. in Tisdale J, Miller D. Drug-Induced Diseases, Prevention, Detection and Management. 3rd edition, 2018 American Society of Health-systems Pharmacists. Bethesda, MD.
Pai AB. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy A Pathophysiologic Approach, Tenth edition, DiPiro J et al eds. Mcgraw Hill. 2015
Pai AB. Iron Oxide Nanoparticles for Treatment of Anemia of Chronic Kidney Disease: Too Much of a Good Thing? R. Bawa (Editor), G. F. Audette and B. E. Reese. (Assistant Editors): Handbook of Clinical Nanomedicine: Law, Business, Regulation, Safety and Risk, Pan Stanford Publishing, Singapore (2015) [ISBN 978-981-4669-22-1]
Pai AB. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy A Pathophysiologic Approach, Ninth edition, DiPiro J et al eds. Mcgraw Hill. 2013
Pai AB. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy A Pathophysiologic Approach, Eighth edition, DiPiro J et al eds. Mcgraw Hill. 2010
Pai AB, Mason DL. Acute Kidney Diseases. in Tisdale J, Miller D. Drug-Induced Diseases, Prevention, Detection and Management. 2nd edition, 2010 American Society of Health-systems Pharmacists. Bethesda, MD.
Pai AB, Pai MP. Acute Renal Diseases. in Tisdale J, Miller D. Drug-Induced Diseases, Prevention, Detection and Management. 2005 American Society of Health-systems Pharmacists. Bethesda, MD.
Pai AB, Rohrschieb M. Disorders of Calcium and Phosphorus Homeostasis. Pharmacotherapy A Pathophysiologic Approach, Seventh edition, DiPiro J et al eds. Mcgraw Hill. 2008
Pai AB, Conner TC. Chronic Kidney Disease in Applied Therapeutics: The Clinical Use of Drugs. 9th Edition, Koda-Kimble et al eds. Lipincott Williams and Wilkins. 2008
GRANTS AWARDED
2016 Addressing the Source of Catheter-microbiota Derived Inflammation: Evaluation of Lipoteichoic Acid as a Potential Clinical Biomarker of Biofilm Burden and Inflammation in Dialysis Patients. Renal Research Institute $110,591 Pai AB (Co-PI, 10% effort), Yessayan L (Co-PI)
2015 A Community Based Study of Adverse Effects of NSAIDs on the Kidney and Risk Mitigation To Reduce Preventable Harm. Food and Drug Administration HHS F223201510132C. $203,733 Pai AB (PI, 10% effort)
2014 A pilot study of monitoring hydration level in hemodialysis patients with multi-channel electrical impedance tomography. General Electric Global Research $25,000, Cardone KE (PI), Pai AB (Co-PI)
2013 An in vitro-in vivo correlation model to predict serum non-transferrin bound iron from intravenous iron compounds. NIH 1U01FD004889, $499,999 Pai AB (PI, 30% effort) Pai MP, Meyer D, Bales, B (Co-Is) 9/15/13-3/14/15
2011 Use of a simple immunoassay to quantitatively assess catheter biofilm to predict systemic inflammatory burden and catheter-related bloodstream risk. Dialysis Clinic Inc. Paul Teschan Research Fund. Pai AB (PI). Mousa S (Co-I), Waldman J (Co-I), Harford A (Co-I). $100,000 (2 years)
2008 Development of a Pilot Chronic Kidney Disease Biomarker Surveillance Cohort: The Albany Pharmacy Biosurveillance (Alpha-Bios) Cohort Study. Scholarship of Discovery Pai AB (PI), Mason DL, (Co-PI), Grabe DW, Pallotta K, Cheng M (Co-Is). $6,000
Effects of 19-nor-1(-dihydroxyvitamin D2 (paricalcitol) versus placebo on oxidative stress and vascular reactivity in CKD patients. Abbott Laboratories. Pai AB (PI), Grabe D, Mason DL Eisele G (Co-Is) $108,000
2006 Effect of Intravenous Ascorbic Acid on Oxidative Stress and Cytokine Activation in Hemodialysis Patients on Intravenous Iron. Pai AB (PI), Conner TA Co-I, Raj DSC, Co-I University of New Mexico General Clinical Research Center $6,982
Cytokine Activation and Oxidative Stress in Hemodialysis Patients Receiving IV Iron. American College of Clinical Pharmacy and University of New Mexico General Clinical Research Center Pai AB (PI), Raj DSC (Co-I) $23,500
Cytokine Activation, Oxidative Stress and Mitochondrial Toxicity Associated with IV Iron Use in Patients on Hemodialysis. Clinical Translational Science Center Pilot Project RFA. Pai AB (PI) Raj DSC, Walker MK, Shah VO. (Co-Is) $50,000
2005 Accuracy of creatinine clearance equations in morbidly obese patients: Influence of central body fat distribution. University of New Mexico General Clinical Research Center $3,080. Pai MP (PI), Pai AB (Co-I), Demirovic J (Co-I)
2004 Effects of Intravenous Iron Sucrose on the Rate of Staphylococcus aureus Growth in Uremic Serum. University of New Mexico Resource Allocation (RAC) Grant. Pai AB (PI), MP Pai (Co-I), Mercier RC (Co-I), Depczynski JC (Co-I) $10,000
2003 Comparison of Markers of Oxidative Stress in Hemodialysis Patients Receiving Iron Dextran, Sodium Ferric Gluconate and Iron Sucrose. American College of Clinical Pharmacy Anemia Research Award and University of New Mexico General Clinical Research Center, $20,946, Pai AB (PI), Zager P (Co-I), Zager R, (Co-I), Norenberg JP (Co-I)
2002 Impact of Clinical Pharmacy Services on Medication Cost and Hospitalization Rates in Hemodialysis Patients. Health Outcomes Research Starter Grant, PhRMA Foundation, $60,000 (2 years) Pai AB (PI), HJ Manley (Co-PI)
Cytochrome P-450 3A4 Activity in Iron Deficient Hemodialysis Patients with Diabetes Mellitus, University of New Mexico General Clinical Research Center, $11,831, Pai AB (PI), Spalding CT (Co-I), Norenberg JP (Co-I)
Grants Submitted
2017 Promoting Early CKD Awareness: A Pharmacist-led Chronic Kidney Disease Education Intervention. Pai AB (PI), Wright-Nunes, J (Co-I), Choe, HM (Co-I). $1,500,000 Status: scored not funded
Implementation of an Anti-Hypertensive Medication Deprescribing Protocol
in Hemodialysis Clinics. Renal Research Institute. Wilund, K. (PI) Pai AB(Co-I). $121,000. Status: Not Funded
Application of an in vitro-in vivo correlation model to compare labile iron release from intravenous iron nanoparticle formulations. FDA BAA 17-00123. Pai AB (PI) Total costs $868,132 Status: Not funded
Redesign of FDA medication guides using data visualization science to support personalization and improve comprehension for patients. FDA BAA 17-00123. Pai AB (PI) Total costs $649,549 Status: Not Funded
2015 Daptomycin pharmacokinetics in home hemodialysis patients. Paul Teschan Research Fund. Dialysis Clinic Inc. Cardone K (PI), Pai AB (Co-I), Salenger P (Co-I). $50,000, June 30, 2015, not funded
2013 Quantitative Hydration Assessment during Hemodialysis Using Multi-frequency and Multi-channel Electrical Impedance Technologies. NIH R21 PA-13-303. Chen X (PI), Pai AB, Cardone K (ACPHS subawardees, total subaward $181,260). Status: Resubmitted 11/16/14 Not Discussed
Addressing the Source of Catheter-related Inflammation: Inhibition of Lipoteichoic Acid Synthesis in Catheter Biofilm with Daptomycin-Anticoagulant Antimicrobial Lock Solutions. Normon S Coplon, Satellite Healthcare, Pai AB (PI), Nicasio (Co-I) $150,000 Status: Not Funded
2012 Medication management by PHArmacists for patients on dialySIS (The EMPHASIS Program),Centers for Medicaid and Medicare Healthcare Innovation Award. $6,839,544 (total). Cardone K (PI), Pai A (Co-PI) Status: Not Funded
2011 Gram-positive vascular access infection in frequent home hemodialysis. Cardone K (PI), Pai AB (Co-I). Baxter Renal Discoveries EGP Grant Program. $375,000 (direct) Status: Not Funded
Pharmacists Reduce Kidney Disease Risks-the PreCKD Program. Pai AB (PI), Cerulli J, Grabe DW, Polimeni J (Faculty Investigators). NIH R15, $300,000 (direct). Status: Not Discussed, Not Funded
Pharmacists Reduce Kidney Disease Risks-the PreCKD Program. Pai AB (PI), Cerulli J, Grabe DW, Polimeni J (Faculty Investigators). NIH R34, $450,000 (direct). Status: Scored but not funded
2010 Comparison of Maintenance Doses of Iron Sucrose on Biomarkers of Oxidative Stress, Inflammation and Vascular Reactivity. Pai AB (PI), Bailie GR, Mason DL. Fresenius Medical Care. $210,000, Status: Not Funded
2009 Catheter Biofilm and Lung Injury in CKD Stage 5. Pai AB, (PI), Johnson A. National Kidney Foundation KDOQI Research Grant. $450,000. Status: Not Funded
A mechanism for lipoteichoic acid-induced lung injury. Pai AB, (PI), Johnson A, (Faculty Investigator). NIH R15 (AREA). $300,000 Status: Scored but not funded
Lipoteichoic acid -induced lung edema during iron supplementation. Johnson A (PI), Pai AB (PI), NIH RC2 (Global Opportunities). $1,300,000. Status: Unscored, Not Funded
Inflammation, Vascular Reactivity and Contractility after Chronic Administration of Intravenous Iron Compounds. Pai AB (PI), Johnson A Co-I, Bailie G (Co-I), AMAG Pharmaceuticals. $185,899 Status: Not Funded
2007 Effect of Relatively Labile and Stable Iron-Carbohydrate Complexes on Cardiomyocyte Mitochondrial Toxicity. RoFAR Foundation. Pai AB (PI). $31,800. Status: Not Funded
Development of an extemporaneous lanthanum carbonate oral suspension. Shire, Inc. Pai AB (PI), Conner TA, Felton L (Co-I’s) $70,000 Status: Status: Not Funded
2006 Cytokine Activation, Oxidative Stress and Mitochondrial Toxicity Associated with IV Iron Use in Patients on Hemodialysis. Clinical Translational Science Center Career Development Award. Pai AB (PI) Raj DSC, Walker MK, Shah VO. (Co-Is) Status: Not Funded
Comparison of Hemoglobin Stability, Oxidative Stress and Vascular Reactivity in Diabetic Hemodialysis Patients with Hyporesponse to rHuEPO. Hoffman-LaRoche, Pai AB (PI) $276,000 Status: Not Funded
CONTRACTS AWARDED
2018 Evaluation of DFO-chelatable labile iron in vitro and in vivo. Rafarm UK, $193,499 Pai AB (PI)
2016 Development of a certificate program for pharmacists for chronic kidney disease management. NIH National Kidney Disease Education Program. $10,000. Pai AB (Program Director)
2012 A Phase 1, Single-Center, Open-Label, Single-Dose Study to Assess the Pharmacokinetics of Ceftaroline Fosamil in Adults Receiving Continuous Renal Replacement Therapy. Forest Research Institute. $224,250, Pai AB (PI), Asif A (Co-I), Cardone KE (Co-I)
2011 A Multi-center, Longitudinal, Observational Study of Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD) to Establish the Rate, Characteristics, and Determinants of Disease Progression. Otsuka Pharmaceuticals, $26,438 Pai AB (PI)
An Observational Prospective Registry to Identify Demographic and Clinical Characteristics of Patients Hospitalized with Euvolemic and Hypervolemic Hyponatremia and Assess the Comparative Effectiveness of Available Treatments and the Impact on Resource Utilization, Otsuka Pharmaceuticals, $92,000 Pai AB (PI)
2006 Evaluation Of Cinacalcet HCl Therapy to Lower Cardiovascular Events
(EVOLVE). Amgen Inc, $213,500, Zager PG, Pai AB (Co-PI)
A Phase III of the Safety and Efficacy of Ferumoxytol Compared with Oral Iron as an Iron Replacement Therapy in Hemodialysis Patients who are Receiving Supplemental Erythropoietin Therapy. Advanced Magnetics. $70,000, Raj DSC (PI), Pai AB (Co-PI)
A Phase II, Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Lanthanum Carbonate for the Reduction of Serum Phosphorous in Subjects with Stage 3 and 4 Chronic Kidney Disease who Have Elevated Serum Phosphorous Levels. Shire Inc. $52,250 Pai AB (PI), Raj D (Co-I)
2005 An open-label multi-center study to document the efficacy, safety and tolerability of long-term administration of RO0503821 in patients with chronic renal anemia. Hoffman-LaRoche. 197,455 Raj D (PI), Pai AB (Co-PI)
A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in chronic kidney disease patients not receiving dialysis. Amgen,Inc. $50,538 Raj D (PI), Pai AB (Co-PI)
2004 A randomized, controlled, open-label, multi-center, parallel-group study to demonstrate the efficacy and safety of RO0503821 when administered intravenously for the maintenance treatment of anemia in patients with chronic kidney disease who are on dialysis Hoffman-LaRoche. $247,581, Raj D (PI), Pai AB (Co-PI)
2003 TARGET: Treatment Strategies to Achieve Recommended K/DOQI Goals in ESRD Subjects on Cinacalcet. Phase II trial Amgen, Inc. $70,181 CT Spalding (PI), Pai AB (Co-PI)
2002 “A Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of an Oral Calcimimetic Agent (AMG 073) When Two Different Vitamin D regimens are Used in Subjects with Secondary Hyperparathyroidism of End-stage Renal Disease (ESRD). Phase II Trial Amgen, Inc. $58,090 CT Spalding (PI) Pai AB (Co-PI)
2001 “A Placebo Controlled, Double-blind, Multicenter Study to Assess the Efficacy and Safety
of an Oral Calcimimetic Agent (073) in Secondary Hyperparathyroidism of Chronic Renal Insufficiency (Hemodialysis and Peritoneal Dialysis)" Phase II Trial. Amgen Inc. $40,220 CT Spalding (PI) Pai AB (Co-PI)
RESEARCH TRAINING
August 2007 Nephrology PRN Mini-Sabbatical
Maine Medical Center Research Institute
Mentor: Thomas Nolin, Pharm.D., PhD.
“Assessment of aminothiol concentrations after IV iron administration”
November 9, 2005 Professional Development Seminar sponsored by Women in Nephrology
American Society of Nephrology Renal Week
(Received $250 travel grant to attend)
March 30, 2004 IRB 101
Public Responsibility in Medicine and Research
Aug 2001-Oct 2003 University of New Mexico General Clinical Research Center
Scholars Program
September 8-10, 2001 Preparing for a Clinical Research Career in Nephrology
Sponsored by National Institute of Diabetes and Digestive and Kidney Diseases and the American Society of Nephrology
October 9-10, 2001 Clinical Research Skills Workshop for Investigators
Sponsored by Pfizer
INVITED PRESENTATIONS AND CONTINUING EDUCATION
Health Literacy Assessments. University of Michigan Integrated Patient-Centered Alliance in Care Transitions. July 18, 2018 University of Michigan, Ann Arbor, MI
Keeping Kidneys Safe: Judicious Use of NSAIDs in High Risk Patients. Updates in Nephrology for the Primary Care Provider. May 5, 2018, Plymouth, MI
Medication Reconciliation, Review and Management, O my!-Whose minding the Med List? National Kidney Foundation Spring Clinical Meeting, April 12, 2018, Austin, TX
Relevant clinical challenges with IV iron formulations. University of Geneva, Geneva, Switzerland, January 22, 2018
Out of the Black. Challenges and opportunities with IV iron formulations. University of Illinois, Nutritional Sciences Seminar series, Champaign, IL, January 17, 2018
Gaps In Bioequivalence Evaluation (BE) of Intravenous Iron Nanoparticle Formulations. National Institute of Standards Technology, Gaithersburg, MD, October 25, 2017
Are we reaching our full potential in dialysis care? Impact of systematic medication reconciliation and management services. CMS Kidney Health Affinity Group. Webinar, September 18, 2017
Gaps in Bioequivalence of Complex Drugs- How Can Global Experience with IV Iron Generics Advance BE? GDUFA FY 2018 Regulatory Science Initiatives Part 15 Public Meeting, Food and Drug Administration, Silver Spring MD, May 3, 2017
Clinically Relevant Differences between RLD and Generic IV iron Formulations. Non-Biologic Complex Drugs Working Group/Vifor Pharma. March 29, 2017, St. Gallen, Switzerland
Assessing a Medication Label Health Literacy Tool focused on NSAIDs. University of Michigan Patient Education and Health Literacy ForUM. February 1, 2017, Ann Arbor, MI
Relevant Clinical Challenges with RLD and generic IV iron formulations. Non-Biologic Complex Drugs Working Group, December 12, 2016, Amsterdam, NL.
Reducing Preventable Harm from Non-steroidal anti-inflammatory Drugs. Health Literacy Research Conference. October 13, 2016, Bethesda, MD
Challenges in Clinical Use of IV Iron Formulations. University of Michigan, College of Pharmacy, Board of Governors. Michigan League, Ann Arbor, MI, September 9, 2016
NSAIDs: Wolves in Sheep’s Clothing? Food and Drug Administration Professional Affairs and Stakeholder Engagement. June 14, 2016, Silver Spring, MD
Relevant Challenges in Determination of Bioequivalence of Generic IV Iron Formulations. GDUFA FY 2017 Regulatory Science Initiatives Part 15 Public Meeting, Food and Drug Administration, Silver Spring MD, May 20, 2016
Judicious Use of IV Iron: Do We Know When the Tank is Full? National Kidney Foundation Spring Clinical Meeting. April 30, 2016, Boston, MA
No NSAIDS? Now What? National Kidney Foundation Spring Clinical Meeting. April 29, 2016, Boston, MA
Mantras to Live By for Dosing in CKD. National Kidney Foundation Spring Clinical Meeting. April 27, 2016, Boston, MA
Biosimilars and non-biologic complex drugs: Current issues. North East Kidney Foundation Kidney Care Conference. Excelsior Springs, Saratoga, NY November 1, 2015
Are we reaching our full potential in CKD care?-Medication management services in CKD. National Institutes of Health, Kidney Interagency Coordinating Committee. Bethesda, MD. September 25, 2015
Pharmacist-led programs to improve medication safety in kidney disease. 4ª Jornada Integrada de Qualidade em Hemodiálise – Programação, São Paulo, Brazil, June 19, 2015
Lipoteichoic acid: potential as a non-invasive marker of biofilm burden. University of São Paulo, Department of Pharmaceutical Sciences. São Paulo, Brazil, June 19, 2015
Clinical Challenges with IV Iron Use in Kidney Disease. GDUFA FY 2015 Regulatory Science Initiatives Part 15 Public Meeting, Silver Spring MD, June 5, 2015
Top Ten Reasons to Have a Pharmacist of the ESKD Team. National Kidney Foundation Spring Clinical Meeting. March 25, 2015, Dallas, Texas
Top Ten Nephrotoxic Drugs. National Kidney Foundation Spring Clinical Meeting. March 26, 2015, Dallas, Texas
Generic IV Iron Formulations: Black Solutions in a Regulatory Gray Area. National Kidney Foundation Spring Clinical Meeting. March 28, 2015, Dallas, Texas
Keeping Kidneys Safe: Counseling High Risk Patients on NSAID Use to Prevent Kidney Injury. NIH National Kidney Disease Education Program Pharmacy Work Group. CE Program, September 2014,
Available online at:
Clinical Use of Iron Oxide Nanoparticles in Chronic Kidney Disease. 12th Annual Current Issues in Medicine Biotech and Pharma. Rensselaer Polytechnic Institute. Troy, NY. September 18, 2014
Safety of Intravenous Iron: Bench to Bedside. Food and Drug Administration, Office of Generic Drugs, Science Team. Silver Springs, MD. July 28, 2014
Medication Management in Chronic Kidney Disease: A Dam Ready to Break. Southern Association of Medicaid Pharmacy Administrators. Annual Meeting. Key West, FL. July 22, 2014
Medication Management in Chronic Kidney Disease: Pharmacotherapy in a House of Mirrors. APhA Annual Meeting and Exposition Orlando, FL, March 31, 2014
Safety Concerns with Intravenous Iron: Bench to Bedside. 3ª Jornada Integrada de Qualidade em Hemodiálise – Programação, São Paulo, Brazil, April 4th, 2014
Calcium and Phosphorus Metabolism in Chronic Kidney Disease and the Management of Hyperphosphatemia. Power Pak CE. November 11, 2013
Safety Intravenous Iron: Bench to Bedside. SUNY Upstate Medical Center, Nephrology Grand Rounds. Syracuse, NY. October 8, 2013
Evidence-Based Screening and Prevention Strategies: Chronic Kidney Disease. Clinical Reasoning Series. American College of Clinical Pharmacy Annual Meeting. Speaker and Moderator. October 12, 2013, Albuquerque, NM.
New an Emerging Agents for Anemia of CKD: Time for a New Direction? American College of Clinical Pharmacy Annual Meeting. Speaker. October 15, 2013, Albuquerque, NM.
Safety Considerations for IV Iron Products: Tips for Current Practice. Albany College of Pharmacy and Health Sciences. April 28, 2013. Albany, NY ACPE 1.0 contact hour
Role of Pharmaceutical Care on Drug Use and Hospitalizations in ESRD Patients. American Society of Nephrology, Renal Week. November 2, 2012, San Diego, CA
Safety Considerations for IV Iron Products: Tips for Current Practice. American Society of Health-systems Pharmacists Mid Year Clinical Meeting and Exhibition. December 6, 2011 New Orleans, LA
Creatinine Clearance Equations-Tips for Current Practice. Albany College of Pharmacy and Health Sciences. October 23, 2011. Albany, NY ACPE 1.0 contact hour
Adverse Events Associated with Intravenous Iron Therapy. American Society of Health-systems Pharmacists Mid Year Clinical Meeting and Exhibition. December 9, 2009, Las Vegas, NV ACPE 3.0 contact hours
Chronic Kidney Disease- Patient Management Pearls. Pharmacy Practice Institute, Albany College of Pharmacy and Health Sciences, March 21, 2009 ACPE 1.0 contact hour
Contemporary issues in drug dosing in kidney disease. Elmhurst Hospital, Queens, NY. May 16, 2012
Safety Intravenous Iron: Contemporary Safety Concerns, Amgen Regional Medical Science Liaisons meeting. Live Webinar July 15, 2011
Safety Intravenous Iron: Bench to Bedside, World Congress of Nephrology, Renal Pharmacists Network, April 8, 2011, Vancouver, BC
Intravenous iron in hemodialysis patients-too much of a good thing? American Chemical Society, March 17, 2010, Albany, NY
Chronic Kidney Disease Patients (CKD 3 and 4): Clinical Pearls for Bridging the Gap between Hospitalization and Outpatient Care. American College of Clinical Pharmacy Annual Meeting. Anaheim, CA. October 20, 2009
Updates in Anemia of CKD: New ESA and Iron Products. Nephrology Noon Conference. University of New Mexico Health Sciences Center March 31, 2008.
Chronic Kidney Disease- a case-based, active learning approach. Program Chair, Speaker and Case Moderator. April 19, 2008, Albuquerque, NM ACPE 8.75 contact hours
Therapeutic Advances in Chronic Kidney Disease: Management of Anemia. Medscape Audio Cybersession. Recorded June 15, 2007. ACPE/CME 1.0 contact hour
Use of Vitamin D Analog Therapy in CKD. Nephrology Noon Conference. University of New Mexico Health Sciences Center December 12, 2006.
Phosphate Binder Therapy in CKD. Nephrology Noon Conference. University of New Mexico Health Sciences Center December 11, 2006
Health Care Disparities in Chronic Kidney Disease. American College of Clinical Pharmacy Annual Meeting October 28, 2006, St. Louis, MO.
Anemia of CKD. Nephrology Noon Conference. University of New Mexico Health Sciences Center. August 28 and 30, 2006
Broader Roles of Vitamin D in Patients with CKD. American College of Clinical Pharmacy, Nephrology PRN Business and Networking Forum. April 8, 2006
Intravenous Iron Therapy: Current Data on Oxidative Stress and Infection. Nephrology Noon Conference. University of New Mexico Health Sciences Center. March 20, 2006
Anemia of Chronic Kidney Disease: Pathophysiology and Treatment: New Mexico Society of Health-systems Pharmacists. May 18 and June 8, 2006, Albuquerque, NM ACPE 176-000-06-010-L01
Role of Cinacalcet in Management of Secondary Hyperparathyroidism. November 18, 2004, Dialysis Clinic Inc., Nurse Managers, Albuquerque, NM
Significant Papers in Pharmacotherapy: Nephrology. October 25, 2004, American College of Clinical Pharmacy Annual Meeting, Dallas, TX.
Iron and Oxidative Stress in Hemodialysis Patients. April 15, 2004, New Mexico Center for Environmental Health Sciences. Renal-Cardiovascular Subcore
Enhancing Patient Adherence: The Role of a Pharmacist. Zambian Pharmaceutical Society Annual General Meeting. June 14, 2003 Mulungushi International Conference Centre, Lusaka, Zambia
Treatment of Hypertension in the Hemodialysis Population. Dialysis Clinic, Inc. Nurse Managers Meeting. April 15, 2003, Dana Point, CA
Anemia of Chronic Kidney Disease: Strategies for Optimizing Treatment. Utah Society of Health-systems Pharmacists. September 7, 2002, Sandy, Utah. ACPE 167-000-02-006-L01
Emerging Treatment for Renal Osteodystrophy. Nephrology Noon Conference. University of New Mexico Health Sciences Center. October 28, 2002
Anemia of CKD, New Strategies for Treatment. Nephrology Noon Conference. University of New Mexico Health Sciences Center. October 16, 2002
Treatment of Hypertension in the Renal Failure Patient. American Nephrology Nurses Association (ANNA), Western Chapter, September 29, 2002, Albuquerque, NM
Pharmacokinetic and Pharmacodynamic Considerations in Renal Failure. Nephrology Noon Conference. University of New Mexico Health Sciences Center. August 28, 2002
Anemia of Chronic Kidney Disease: Strategies for Optimizing Treatment. New Mexico Society of Health-systems Pharmacists. July 11, 2002, Albuquerque, NM. ACPE 176-000-02-008-LO1
Pharmacological Management of Hypertension in Hemodialysis Patients. New Mexico Council on Renal Nutrition, July 19, 2002, Albuquerque,NM
Optimizing Anemia Management in ESRD, New Mexico Society of Health-systems Pharmacists Annual Meeting, October 8, 2001, Albuquerque, NM
Treatment of Hypertension in the Hemodialysis Population. Fellowship Seminar, Faculty/Residents University of Illinois at Chicago, November 1999
Management of Anemia and Bone Disease in ESRD. Faculty/PharmD students University of Illinois at Chicago, August 1999, February 2000
Evaluating Diuretic Resistance and Implementation of Therapeutic Substitution; Torsemide for Bumetanide. Barton AB, Carson J, Lombardi TP. Third Annual Sister Katherine Graber Research Forum. plementary Methods of Cardiac Care Delivery, Albany, New York, April 1997; 2.16th Annual Eastern States Conference for Pharmacy Residents and Preceptors. Baltimore, Maryland, May 1997.
Anti-Tumor Necrosis Factor in Treatment of Rheumatoid Arthritis. Doctor of Pharmacy Seminar, Albany College of Pharmacy, Albany, NY November 1997
Torsemide as An Alternative to Bumetanide.St. Peter’s Hospital Department of Nursing, Albany, NY February 1997
Circumventing Diuretic Resistance.1. St. Peter’s Hospital Staff, Albany, NY September 1996 2. St. Peter’s Hospital Medicine and Family Practice Residents, Albany, NY February, 1997
Pharmacokinetics of Meperidine in Fetal Sheep. Albany College of Pharmacy Biopharmaceutics, Albany, NY November 1995
TEACHING AND MENTORING
September 2017 Pharm 570 Early Patient-centered Care Experience
University of Michigan College of Pharmacy
Cecelia Li P2
Rona Jin P2
Dana Alkhouli P3
Noor Hermiz P3
Krysta Walter P3
Diana Michaels P3
Rebecca Smrke P3
September 2017 Pharm 200 Science of Medicines
University of Michigan College of Pharmacy
BS Pharmaceutical Sciences
Insuring your health
Being mortal
An ounce of prevention
Don’t forget to take your pills
Megatrends in health
May 2017 Clinical and Translational Post-Doctoral Fellowship
University of Michigan College of Pharmacy
Marcus Luiz, PharmD, PhD (2016)
January 2017 Pharm 514 Pharmacy Practice Skills II
University of Michigan College of Pharmacy
Course coordinator
Pharm 612 Therapeutic Problem Solving II
University of Michigan College of Pharmacy
Instructor: Anemia
January 2017 Pharm 570 Early Patient-centered Care Experience
University of Michigan College of Pharmacy
Ben Furbacher P3
Emily Han P3
Madeline Lipp P3
Humaira Nawer P3
July 2016-present PharmD Investigations
University of Michigan College of Pharmacy
Genevra Galura 2019
Yiwei Yin 2019
Karen Davidge 2019
Rebecca Smrke 2020
Anisa Bici 2020
Jack Lukas 2020
Eunice Lee 2020
Joseph Haroney 2021
Johanna Goeman 2021
July 2015-2016 Co-Director, PGY2 Nephrology Residency
Nicole Wegryzn, Pharm.D. (2015-2016)
May 2014-August 2014 Research Mentor: University of São Paulo fellowship program
Geisa Otani
August 2013 Early Patient Care Elective
Participants:
Adam Hoye-Simek, Class 2016
David Hughes, Class 2016
Jeffrey Bettinger Class 2017
Andrea Glowgowski Class 2017
Christopher Bartolillo Class 2017
July 2013-June 2014 Mentor, Teaching and Learning Program
Amanda Rennick, Pharm.D. PGY 1 resident
Stratton VA Medical Center, Albany, NY
July 2013-June 2014 Director, Nephrology Pharmacotherapy Residency
Soo Min Cho, Pharm.D. (2013-2014)
Feb 2013-Sept 2013 Primary Mentor: University of São Paulo fellowship program
Daniele Alcantara
July 2012-2013 Director, Nephrology Pharmacotherapy Fellowship
Fellows: Adinoyi Garba, PharmD (2012-2013)
2011-2016 Integrated Problem Solving Workshop 6
Course Coordinator and Facilitator
2011-2016 Advanced Nephrology
Acute Kidney Injury, Clinical Pharmacokinetics
PharmD (elective)
Aug 2010-Aug 2013 Pharmacology, Therapeutics, Pathophysiology and Medicinal Chemistry
Prevention of Progression of CKD, Anemia, Acute Kidney Injury Acid-Base Disorders
2010-2016 Nephrology Patient Care
Albany College of Pharmacy and Health Sciences
Acute Kidney Injury, Clinical Pharmacokinetics
PharmD (elective)
2009-2016 Independent Research Study
Heena Patel, Class 2012
Dara Becker, Class 2013
Natsuki Kubotera, Class 2013
Alex Prokopienko, Class 2014
Mara Garfinkel Class of 2016
2009-2016 Mentor, Summer Research Award
Albany College of Pharmacy and Health Sciences
Heena Patel, Class 2012
Dara Becker, Class 2013
Natsuki Kubotera, Class 2013
Alex Prokopienko, Class 2014
Bradley Teoh, Class 2014
2009-2016 Advanced Pharmacy Practice Experience
Albany College of Pharmacy and Health Sciences
Clinical Nephrology
10-12 students per year
2009-2014 Director, Clinical Pharmacy Research Training Program
Albany College of Pharmacy and Health Sciences
Program participants:
Heena Patel, Class 2012
Natsuki Kubotera, Class 2013
Alex Prokopienko, Class 2014
Feb 2009 Pharmacotherapy IV
Albany College of Pharmacy and Health Sciences
Pharmacokinetics and drug metabolism in chronic kidney disease, acute kidney injury
Jan 2009-May 2009 Seminar I
Albany College of Pharmacy and Health Sciences
Oct 2008-Dec 2008 Seminar II
Albany College of Pharmacy and Health Sciences
Feb 2007, Sept 2009, University of Florida, Working Professionals Doctor of Pharmacy Degree
Sept 2011 Program, End-stage Renal Disease and Dialysis
July 2006-Jun 2008 Director, Nephrology Pharmacotherapy Fellowship
University of New Mexico, College of Pharmacy
Fellows: Todd Conner, Pharm.D. (2006-2008)
May 2006-Oct 2008 Director and Preceptor, Early Patient-Oriented Care Internship
University of New Mexico, College of Pharmacy
Program participants:
Alex Boyd, Class 2008 Summer Bryan, Class 2009
Alicia Chavez, Class 2009 Vienna Heindl, Class 2009
Charles McQuade, Class 2010 Maggie Post Class 2010
Lynette Wasson Class 2009
Sept 2005-Oct 2008 Director, Clinical Pharmacy Research Training Program
University of New Mexico, College of Pharmacy
Program participants:
Alex Boyd, Class 2008 Charles McQuade Class 2010
Alicia Chavez, Class 2009 Gavyn Thomas Class 2013
Marshall Caraveo pre-pharmacy
Jul 2003-Jul 2005 Director, Specialized Residency in Nephrology Pharmacotherapy
University of New Mexico, College of Pharmacy
Residents: Joseph Depczynski, Pharm.D. (2003-2004)
Isela Martinez, Pharm.D. (2004-2005)
2008 Pharm 739 Pharmacotherapy I
University of New Mexico, College of Pharmacy, Albuquerque, NM
Renal Module: Acute and Chronic Kidney Disease, Drug-Induced Renal Disease, Dialysis-Related Complications
2007-2008 Pharm 726 Pharmacokinetics and Biopharmaceutics
University of New Mexico, College of Pharmacy, Albuquerque, NM
Drug Dosing in Renal Failure, Quantification of Renal Function
Jan 2007 Pharm 798 Problems in Pharmacy
Students gain early clinical experience with patient and health professional interaction, critical literature review and patient presentation skills at an outpatient hemodialysis unit.
2002-2004 Pharm 716 Practical Patient Experience
University of New Mexico, College of Pharmacy, Albuquerque, NM
6 students per year
2002-2007 Pharm 751 Pharmacotherapy
University of New Mexico, College of Pharmacy, Albuquerque, NM
Renal Module: Acute and Chronic Kidney Disease, Drug-Induced Renal Disease, Dialysis-Related Complications, Glomerulonephritis
2001-present Pharm 770 Clinical Clerkships
University of New Mexico, College of Pharmacy, Albuquerque, NM
6 to 8 students per year
2001-2007 Pharm 745 Clinical Pharmacokinetics
University of New Mexico, College of Pharmacy, Albuquerque, NM
Drug Dosing in Renal Failure, Quantification of Renal Function
2001-2007 Pharm 711/712, 721/722 731 Problem-Based Learning
University of New Mexico, College of Pharmacy, Albuquerque, NM
8 to 16 students per year
Jan – Feb 2000/2001 PHAR 407 Principles of Drug Action and Therapeutics
University of Illinois, College of Pharmacy, Chicago, IL
Drug Use in Renal Failure: Teaching Assistant
Chronic Renal Failure: Lecturer
Acute Renal Failure: Teaching Assistant
Feb 2000/2001 PMPR 370 Pharmacy Grand Rounds
University of Illinois, College of Pharmacy, Chicago, IL
Anemia and Bone Disease in End-Stage Renal Disease: Lecturer
Aug- Sept 1999 Ambulatory Care Lecture Series
University of Illinois, College of Pharmacy, Chicago, IL
End-Stage Renal Disease
GRADUATE STUDENTS
2018 Tiziana DiFrancesco (PhD candidate)
University of Geneva
Dissertation Jury
2016 Sumit Chabra, RPh, MS (PhD candidate)
University of Michigan
Dissertation Committee
August 2009 Jaclyn Hosmer (MS in Pharmaceutical Sciences)
Albany College of Pharmacy and Health Sciences
Thesis Committee
TEACHING TRAINING
August 4-6, 2002 Jump Start for New Faculty
Albany College of Pharmacy, Albany, NY
EDITORIAL AND GRANT REVIEW
September 2017 Invited Reviewer
AACP New Investigator Awards
Feb 2016 Invited Reviewer
NIH RFA DK-15009, Translational Research to Improve Outcomes in Kidney Diseases (R18)
May 2015 Abstract Category Chair
Pharmacokinetics (PK)/Pharmacodynamics (PD)/Pharmacogenomics
American Society of Nephrology
April 2015 Editorial Board, Brazilian Journal of Nephrology
3-year appointment
May 2014 Abstract Category Chair
CKD: Health Services, Prevention
American Society of Nephrology
August 2013 PSAP Reviewer
“Chronic Diseases-Chronic Kidney Disease”
May 2013 Abstract Reviewer
American Society of Nephrology
July 2012 Editorial Board, Advances in Chronic Kidney Disease
3-year appointment
June 2011 Editorial Board, Journal of Nephrology and Therapeutics
September 2010 Co-Editor, Advances in Chronic Kidney Diseases
Optimizing Pharmacotherapy in CKD
2005 Reviewer, National Kidney Foundation Kidney Disease Outcomes Quality Initiative (K/DOQI) clinical practice guidelines
“Anemia in Chronic Kidney Disease”
2004 Reviewer: Immunosuppressants. Contemporary Nephrology Nursing. Pitman, NJ: American Nephrology Nurses Association, 2006 Pitman, NJ: American Nephrology Nurses Association.
2003 Reviewer, National Kidney Foundation Kidney Disease
Outcomes Quality Initiative (K/DOQI) clinical practice guidelines “Blood Pressure Management and Use of Antihypertensive Agents in Chronic Kidney Disease”
2002-2008 Editorial Advisory Board, Dialysis and Transplantation
2002-2008 Associate Editor, Kidney: A Current Survey of World Literature
2000- 2002 Editorial Assistant, Kidney: A Current Survey of World Literature
JOURNALS REVIEWED
Health Literacy Research and Practice
Clinical Journal of American Society of Nephrology
Clinical Pharmacokinetics
Nanomedicine
BMC Nephrology
Pediatric Nephrology
Hemodialysis International
Journal of Clinical Pharmacology
Health Affairs
Journal of Managed Care Pharmacy
Journal of Renal Nutrition
Journal of Clinical Pharmacology
Clinical Pharmacology and Therapeutics
American Journal of Kidney Disease
American Journal of Health-Systems Pharmacy
Peritoneal Dialysis International
Kidney International
American Journal of Nephrology
International Journal of Clinical Practice
Dialysis and Transplantation
Pharmacotherapy
Journal of Medical Economics
PROFESSIONAL SERVICE
April 2018 Elected Research Institute Trustee
American College of Clinical Pharmacy
April 2017 CMS Quality Measures Technical Expert Panel
End-stage Renal Disease Medication Reconciliation and Review
January 2017 Elected Representative
American College of Clinical Pharmacy Nephrology PRN to
Kidney Health Initiative
April 2016-present Steering committee member, Prioritizing Symptoms of ESRD Patients for Developing Therapeutic Intervention" Workgroup, Kidney Health Initiative
February 2015 Invited member, 2016 National Kidney Foundation Spring Clinical Meeting Programming Committee
March 2014 Invited member, Kidney Disease Improving Global Outcomes (KDIGO) Controversies Conference on Iron Management in Chronic Kidney Disease, March 29-31, 2014, San Francisco, CA.
February 2014 Invited member, 2015 National Kidney Foundation Spring Clinical Meeting Programming Committee
August 2014 Member, Women Faculty Special Interest Group (SIG)
American Association of Colleges of Pharmacy
August 2014 Member, Global Pharmacy Education (SIG)
American Association of Colleges of Pharmacy
May 2013 Invited member, ASN Kidney Week Review Task Force
December 2012 ACCP Volunteer Recognition Program, recognition for contributions to NY State Chapter of ACCP
Dec 2012-Dec 2013 President
New York State Chapter of ACCP
January 2012 Chair, Pharmacy Work Group
NIH-National Kidney Disease Education Program (NKDEP)
December 2011 President-elect 2012
New York State Chapter of ACCP
Oct 2011-Sep 2014 Member, American Society of Nephrology
Dialysis Advisory Group
August 2011 Member, Coordinating Panel
NIH-National Kidney Disease Education Program (NKDEP)
August 2011 Member, Programming Committee New York State Chapter of ACCP
June 2011-2016 Chair
New York State Kidney Disease Coalition
March 2011 Member, Renal Research Institute
Programming Committee
September 2010 Member, Pharmacy Advisory Committee
NIH-National Kidney Disease Education Panel
August 2006 College of Pharmacy Student Liaison
American College of Clinical Pharmacy
University of New Mexico
July 2005 Pharmacy Administration Faculty Search committee
April 2005 Contributor
Center for Medicaid and Medicare Services ESRD Program
Technical Expert Panel
Apr 2005 Member
Clinical Trials Center Steering Committee
University of New Mexico Health Sciences Center
Oct 2005-Oct 2006 Chair
Nephrology Practice and Research Network
American College of Clinical Pharmacy
Oct 2003-2005 Chair, Communications Committee
Nephrology Practice and Research Network
American College of Clinical Pharmacy
ACADEMIC SERVICE
June 2018 Elected Member, Executive Committee
University of Michigan
College of Pharmacy
September 2017 Co-Chair Faculty Development Committee
University of Michigan
College of Pharmacy
May 2017 Chair, Search Committee Chair
Tenure track Informatics
University of Michigan
College of Pharmacy
September 2016 Chair, Clinical Pharmacy Strategic Planning: Research Foci
University of Michigan
College of Pharmacy
September 2016 Faculty Development Committee
University of Michigan
College of Pharmacy
September 2016 Clinical Skills Committee
University of Michigan
College of Pharmacy
September 2016 Pharmacy Admissions Committee
University of Michigan
College of Pharmacy
April 2010 Chair, ACPE Self Study
Curriculum subcommittee
August 2009 Advisor, ACCP Student Affiliate/Chapter
Albany College of Pharmacy and Health Sciences
August 2009 Member, Graduate Admissions Committee
Albany College of Pharmacy and Health Sciences
June 2009-Nov 2012 Co-Chair
Pharmacy Curriculum Committee
Albany College of Pharmacy and Health Sciences
March 2009 Member, Graduate Council
Albany College of Pharmacy and Health Sciences
Mar 2009-Mar 2010 Member, Institutional Biosafety Committee
Albany College of Pharmacy and Health Sciences
Oct 2008- Nov 2012 Pharmacy Curriculum Committee, Member
Albany College of Pharmacy and Health Sciences
October 2008 College of Pharmacy Student Liaison
American College of Clinical Pharmacy
Albany College of Pharmacy and Health Sciences
August 2007 OPEC Research Sub-committee
University of New Mexico
September 2006 Pharmacy Practice Reimbursement Committee
University of New Mexico
2003-2005 Associate Member
New Mexico Center for Environmental Health Sciences
Cardiovascular/Renal Toxicology Subcore
NIEHS Grant P30 ES-012072
2003-2005 Coordinator, New Mexico Residents’ and Fellows’ Journal Club
2003-2006 Strategic Planning Committee
University of New Mexico, College of Pharmacy, Albuquerque, NM
2003 Jul 2006 Residency Committee
University of New Mexico, College of Pharmacy, Albuquerque, NM
2002 Oct 2003 Communications Committee
Nephrology Practice and Research Network
American College of Clinical Pharmacy
2002 Psychiatric Faculty Search Committee
University of New Mexico, College of Pharmacy, Albuquerque, NM
2001-2003 Student Services Committee
University of New Mexico, College of Pharmacy, Albuquerque, NM
COMMUNITY SERVICE
March 2018 Kidney Sunday, Fellowship Chapel, Detroit, MI
September 2017 Ask a Pharmacist CDC Diabetes Prevention Program
Livonia, MI
March 2017 Kidney Sunday, Fellowship Chapel, Detroit, MI
October 2015 Stand Down for Veterans, Colonie Elks Club, Latham, NY
Faculty mentor for Cardiovascular and Renal (CaRe) Screening for the ACPHS student chapter of the American College of Clinical Pharmacy. Provides free screening to underserved populations.
2012-2016 Health Care Expo, Albany College of Pharmacy and Health Sciences
Faculty mentor for Cardiovascular and Renal (CaRe) Screening for the ACPHS student chapter of the American College of Clinical Pharmacy. Provides free screening to underserved populations.
October 2014 O+Festival, Kingston, NY
The O+ festival provides free health service and counseling for local artists and underserved populations. Faculty mentor for Cardiovascular and Renal (CaRe) Screening for the ACPHS student chapter of the American College of Clinical Pharmacy.
October 2014 Catwalk for Kidneys, Saratoga, NY
Participant to support Northeast Kidney Foundation (NeKF)
2008-2016 Visiting Scientist
Voorheesville Elementary School Science Fair
June 2012 Young Women in Science Program
Bard College at Simon’s Rock
Great Barrington, MA
May 2007 Special Awards Judge
Intel International Science and Engineering Fair
Albuquerque, NM
2005-2008 Grant Coordinator
The Montessori Elementary School
Identifed, coordinated and wrote grants to support school development and activities
Funded grants: Jul 2006 Elementary Arts Education Program, New Mexico Public Education Department, $29,511
Submitted grants: PNM Classroom innovation
2006, 2008 (funded $3,000)
BP A+ for Energy, 2008
2002 Judge, Medicine/Microbiology/Gerontology
Rio Rancho High School Research Expo
HONORS AND AWARDS
2016 Professional Organization Advisor of the Year (ACCP)
Albany College of Pharmacy and Health Sciences
Advisor of the Year
2016 Fellow, National Kidney Foundation
2014 ACCP Member Spotlight, September 2014
Membership Spotlight 2014
2014 ACCP Volunteer Recognition
Volunteer Recognition 2014
2014 Advisor of the Year, Albany College of Pharmacy and Health Sciences
2010 Fellow, American College of Clinical Pharmacy
2004 Fellow, American Society of Nephrology
1999 Pfizer Experiential Award for Clerkship Excellence
1996 APhA-ASP Professionalism Award Sponsored by McNeil
1994 Rho Chi Pharmaceutical Honor Society
1993-1999 Deans List Albany College of Pharmacy
1993 Dutchess United Educators Award for Academic Excellence
1993. Deans List Dutchess Community College
PROFESSIONAL AFFILIATIONS
2011-present Member, International BioIron Society
2010 American College of Clinical Pharmacy, Fellow
2009-2016 Member
New York State Chapter of the American College of Clinical Pharmacy
2009-2016 Member, American Thoracic Society
2002-2016 American Heart Association, Council on the Kidney in Cardiovascular Disease, Member
2001-present American Association of Colleges of Pharmacy, Active Member
2001-present National Kidney Foundation
2001-present International Society of Nephrology
1999- present American Society of Nephrology, Fellow
2001-2008 New Mexico Society of Health-systems Pharmacists
2003-2010 American College of Clinical Pharmacy, Full Member
1997-2003 American College of Clinical Pharmacy, Associate Member
1996-1999 Pharmaceutical Society of the State of New York
1996-present American Society of Health-system Pharmacists
1996-1999 New York State Council of Health-systems Pharmacists
1994 Rho Pi Phi Pharmaceutical Fraternity
1994 Rho Chi Pharmaceutical Honor Society, Gamma Gamma Chapter
1995-1996 Secretary
July 14, 2018
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- david burns cognitive distortions worksheet
- david burns worksheets pdf
- burns cognitive distortions pdf
- david burns feeling good worksheets
- david burns cbt worksheets
- ken burns ww2 documentary
- ken burns the war episodes
- ken burns the war pbs
- the war ken burns dvd
- ken burns the war netflix
- ken burns the war online free
- best ken burns documentaries